Molecular structure of AZD2014, CAS Number: 1009298-59-2
AZD2014 (CAS 1009298-59-2)
See product citations (2)
Alternate Names:
Vistusertib AZD-2014 Vistusertib [INN] AZD 2014 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide
Application:
AZD2014 is a selective inhibitor of mTOR
CAS Number:
1009298-59-2
Purity:
≥98%
Molecular Weight:
462.54
Molecular Formula:
C25H30N6O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AZD2014 is a selective inhibitor of mTOR. AZD2014 decreases p4EBP1 Thr37/46, inhibits the translation initiation complex and decreases overall protein synthesis. AZD2014 also inhibits the mTORC2 biomarkers pAKTSer473 and pNDRG1 Thr346. AZD2014 inhibits proliferation and induces cell death in breast cancer cell lines, including ER+ cell lines with acquired resistance to hormone therapy.
AZD2014 (CAS 1009298-59-2) References
- The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. | Kahn, J., et al. 2014. Neuro Oncol. 16: 29-37. PMID: 24311635
- Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. | Liao, H., et al. 2015. Am J Cancer Res. 5: 125-39. PMID: 25628925
- AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. | Guichard, SM., et al. 2015. Mol Cancer Ther. 14: 2508-18. PMID: 26358751
- AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest. | Yu, CC., et al. 2016. PLoS One. 11: e0151942. PMID: 27031247
- Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. | Flannery, PC., et al. 2018. Oncol Rep. 39: 455-464. PMID: 29207163
- Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma. | Milošević, Z., et al. 2018. Cell Oncol (Dordr). 41: 409-426. PMID: 29790111
- Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia. | Hadley, G., et al. 2019. Neurosci Lett. 706: 223-230. PMID: 31100427
- An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells. | Mizutani, Y., et al. 2019. Int J Hematol. 110: 490-499. PMID: 31286402
- Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. | Lee, J., et al. 2019. Cancer Discov. 9: 1388-1405. PMID: 31315834
- Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells. | Ahmed, AR., et al. 2020. J Photochem Photobiol B. 213: 112055. PMID: 33142217
- Inhibiting mTOR activity using AZD2014 increases autophagy in the mouse cerebral cortex. | Bensalem, J., et al. 2021. Neuropharmacology. 190: 108541. PMID: 33794244
- [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice]. | Liao, H., et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41: 1056-1061. PMID: 34308856
- Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth. | Pi, R., et al. 2021. Cancer Lett. 523: 72-81. PMID: 34560229
- AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo. | Cha, BH., et al. 2021. J Biol Eng. 15: 24. PMID: 34674743
- [The dual mTORC1/2 inhibitor AZD2014 inhibits acute graft rejection in a rat liver transplantation model]. | Liao, H., et al. 2022. Nan Fang Yi Ke Da Xue Xue Bao. 42: 598-603. PMID: 35527497
Inhibitor of:
1700020N15Rik, 1700021F02Rik, 4E-BP1, 5430416O09Rik, 5830482F20Rik, 9430016H08Rik, ADAL, ADCK5, C030039L03Rik, C4orf3, Cbl-b, Cytokeratin 12, DRG1, EG245651, EIF3S6IP, Gln3, HSN2, IMPACT, mTOR, NPRL2, Olr1128, Rag A, Rag C, Raptor, SEN15, Ser/Thr Protein Kinase, SMG1, SPATA17, STK33, Sval1, TFE3, TOB2, TORC2, Trav12d-1, Ypk1, ZNF486, and ZNF492.Activator of:
Cytokeratin 19, MCM6, MOB1A, and PTCD3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AZD2014, 5 mg | sc-364420 | 5 mg | $303.00 |